Stakeholders comment on FDA's benefit-risk framework

Two sets of stakeholders expressed support for FDA's proposed benefit-risk assessment framework and stressed the need for greater predictability in the review process. The Pharmaceutical Research and Manufacturers of America (see BioCentury, March 25). ...